Europe Uterine Cancer Drug Market - Industry Trends and Forecast to 2032

List of Tables

The Europe uterine cancer drugs market is expected to reach USD 1,251,870.80 million by 2030 from USD 684,672.98 million in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.

Market Segmentation

Europe Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and rest of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Uterine Cancer Drugs Market Dynamics

Driver
Rising incidence of uterine cancer worldwide
Restraint
High cost of uterine cancer treatment
Opportunity
Advancement in genomic profiling and biomarker discovery

Market Players

Some of the major market players operating in the Europe uterine cancer drugs market are listed below:

Baxter
Eli Lilly and Company
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd.
Fresenius SE & Co. KGaA
Viatris Inc.
Sanofi
Teva Pharmaceuticals USA, Inc.
Amneal Pharmaceuticals LLC
Merck & Co., Inc.
GSK plc.
Eisai Co., Ltd.
Pfizer Inc.
Getwell Oncology

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DRUGS MARKET 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25

2 MARKET SEGMENTATION 28

2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 CANCER TYPE LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39

3 EXECUTIVE SUMMARY 40

4 PREMIUM INSIGHTS 43

4.1 PESTEL'S MODEL 44
4.2 PORTER'S 5 FORCES 45
4.3 EPIDEMIOLOGY 46

5 EUROPE UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK 47

5.1 OVERVIEW 47
5.2 REGULATION IN THE U.S. 48
5.3 REGULATION IN CANADA 48
5.4 REGULATION IN EUROPE 48
5.5 REGULATION IN CHINA 48
5.6 REGULATION IN JAPAN 48
5.7 REGULATION IN AUSTRALIA 49
5.8 REGULATION IN INDIA 49
5.9 REGULATION IN BRAZIL 49
5.10 REGULATION IN SOUTH AFRICA 49

6 MARKET OVERVIEW 50

6.1 DRIVERS 52
- 6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE 52
- 6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER 53
- 6.1.3 RISING AWARENESS OF UTERINE CANCER 54
- 6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS 55
6.2 RESTRAINTS 56
- 6.2.1 HIGH COST OF UTERINE CANCER TREATMENT 56
- 6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS 57
6.3 OPPORTUNITIES 58
- 6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY 58
- 6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT 59
6.4 CHALLENGES 60
- 6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET 60
- 6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER 61

7 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE 63

7.1 OVERVIEW 64
7.2 ENDOMETRIAL CANCER 67
- 7.2.1 UTERINE CARCINOSARCOMA 68
- 7.2.2 SEROUS ADENOSARCOMA 68
- 7.2.3 ADENOSQUAMOUS CARCINOMA 68
- 7.2.4 OTHER 68
7.3 UTERINE SARCOMA 69
- 7.3.1 UTERINE LEIOMYOSARCOMA 69
- 7.3.2 ENDOMETRIAL STROMAL SARCOMAS 69
- 7.3.3 UNDIFFERENTIATED SARCOMA 70

8 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE 71

8.1 OVERVIEW 72
8.2 CHEMOTHERAPY 75
- 8.2.1 PACLITAXEL 76
- 8.2.2 CARBOPLATIN 76
- 8.2.3 CISPLATIN 76
- 8.2.4 DOXORUBICIN 76
- 8.2.5 DOCETAXEL 76
- 8.2.6 OTHERS 76
8.3 IMMUNOTHERAPY 77
8.4 HORMONE THERAPY 77
- 8.4.1 PROGESTINS 78
  - 8.4.1.1 MEDROXYPROGESTERONE ACETATE 78
  - 8.4.1.2 OTHERS 78
- 8.4.2 AROMATASE INHIBITORS 79
  - 8.4.2.1 LETRAZOLE 79
  - 8.4.2.2 ANASTRAZOLE 79
  - 8.4.2.3 EXEMESTANE 79
- 8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS 80
  - 8.4.3.1 GOSERELIN 80
  - 8.4.3.2 LEUPROLIDE 80
- 8.4.4 OTHERS 80
8.5 TARGETED THERAPY 81
- 8.5.1 LENVATINAB 81
- 8.5.2 BEVACIZUMAB 81
- 8.5.3 MTOR INHIBITORS 81
  - 8.5.3.1 EVEROLIMUS 82
  - 8.5.3.2 TEMSIROLIMUS 82
8.6 OTHERS 82

9 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE 83

9.1 OVERVIEW 84
9.2 GENERICS 87
9.3 BRANDED 87
- 9.3.1 KEYTRUDA 88
- 9.3.2 LENVIMA 88
- 9.3.3 PROVERA 89
- 9.3.4 TEMODAR 89
- 9.3.5 JEMPERLI 89
- 9.3.6 OTHERS 89

10 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP 90

10.1 OVERVIEW 91
10.2 GERIATRIC 94
10.3 ADULTS 94

11 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION 95

11.1 OVERVIEW 96
11.2 PARENTERAL 99
11.3 ORAL 99

12 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER 100

12.1 OVERVIEW 101
12.2 HOSPITALS 104
- 12.2.1 PRIVATE 104
- 12.2.2 PUBLIC 104
12.3 CANCER CENTERS 105
12.4 SPECIALTY CLINICS 105
12.5 OTHERS 106

13 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL 107

13.1 OVERVIEW 108
13.2 DIRECT TENDER 111
13.3 RETAIL SALES 111
- 13.3.1 HOSPITAL PHARMACY 112
- 13.3.2 RETAIL PHARMACY 112
- 13.3.3 ONLINE PHARMACY 112
13.4 OTHERS 113

14 EUROPE UTERINE CANCER DRUGS MARKET, BY REGION 114

14.1 EUROPE 117
- 14.1.1 GERMANY 123
- 14.1.2 U.K. 128
- 14.1.3 FRANCE 133
- 14.1.4 RUSSIA 138
- 14.1.5 ITALY 143
- 14.1.6 SPAIN 148
- 14.1.7 TURKEY 153
- 14.1.8 BELGIUM 158
- 14.1.9 NETHERLANDS 163
- 14.1.10 SWITZERLAND 168
- 14.1.11 REST OF EUROPE 173

15 EUROPE UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE 174

15.1 COMPANY SHARE ANALYSIS: EUROPE 174

16 SWOT ANALYSIS 175

17 COMPANY PROFILES 176

17.1 MERCK & CO., INC. 176
- 17.1.1 COMPANY SNAPSHOT 176
- 17.1.2 REVENUE ANALYSIS 176
- 17.1.3 COMPANY SHARE ANALYSIS 177
- 17.1.4 PRODUCT PORTFOLIO 177
- 17.1.5 RECENT DEVELOPMENT 178
17.2 EISAI CO., LTD. 179
- 17.2.1 COMPANY SNAPSHOT 179
- 17.2.2 REVENUE ANALYSIS 179
- 17.2.3 COMPANY SHARE ANALYSIS 180
- 17.2.4 PRODUCT PORTFOLIO 180
- 17.2.5 RECENT DEVELOPMENT 180
- 17.2.6 RECENT DEVELOPMENT 181
17.3 SANOFI 182
- 17.3.1 COMPANY SNAPSHOT 182
- 17.3.2 REVENUE ANALYSIS 182
- 17.3.3 COMPANY SHARE ANALYSIS 183
- 17.3.4 PRODUCT PORTFOLIO 183
- 17.3.5 RECENT DEVELOPMENT 184
17.4 PFIZER INC. 185
- 17.4.1 COMPANY SNAPSHOT 185
- 17.4.2 REVENUE ANALYSIS 185
- 17.4.3 COMPANY SHARE ANALYSIS 186
- 17.4.4 PRODUCT PORTFOLIO 186
- 17.4.5 RECENT DEVELOPMENT 188
17.5 TEVA PHARMACEUTICALS USA, INC. 189
- 17.5.1 COMPANY SNAPSHOT 189
- 17.5.2 REVENUE ANALYSIS 189
- 17.5.3 PRODUCT PORTFOLIO 190
- 17.5.4 RECENT DEVELOPMENT 190
17.6 ACCORD HEALTHCARE US. 191
- 17.6.1 COMPANY SNAPSHOT 191
- 17.6.2 PRODUCT PORTFOLIO 191
- 17.6.3 RECENT DEVELOPMENT 191
17.7 AMNEAL PHARMACEUTICALS LLC 192
- 17.7.1 COMPANY SNAPSHOT 192
- 17.7.2 REVENUE ANALYSIS 192
- 17.7.3 PRODUCT PORTFOLIO 193
- 17.7.4 RECENT DEVELOPMENT 193
17.8 BAXTER 194
- 17.8.1 COMPANY SNAPSHOT 194
- 17.8.2 REVENUE ANALYSIS 194
- 17.8.3 COMPANY SHARE ANALYSIS 195
- 17.8.4 PRODUCT PORTFOLIO 195
- 17.8.5 RECENT DEVELOPMENT 195
17.9 ELI LILLY AND COMPANY 196
- 17.9.1 COMPANY SNAPSHOT 196
- 17.9.2 REVENUE ANALYSIS 197
- 17.9.3 PRODUCT PORTFOLIO 197
- 17.9.4 RECENT DEVELOPMENT 198
17.10 GETWELL ONCOLOGY 199
- 17.10.1 COMPANY SNAPSHOT 199
- 17.10.2 PRODUCT PORTFOLIO 199
- 17.10.3 RECENT DEVELOPMENT 202
17.11 GSK PLC. 203
- 17.11.1 COMPANY SNAPSHOT 203
- 17.11.2 REVENUE ANALYSIS 203
- 17.11.3 PRODUCT PORTFOLIO 204
- 17.11.4 RECENT DEVELOPMENT 204
17.12 HIKMA PHARMACEUTICALS PLC 205
- 17.12.1 COMPANY SNAPSHOT 205
- 17.12.2 REVENUE ANALYSIS 205
- 17.12.3 PRODUCT PORTFOLIO 206
- 17.12.4 RECENT DEVELOPMENT 206
17.13 SUN PHARMACEUTICAL INDUSTRIES LTD. 207
- 17.13.1 COMPANY SNAPSHOT 207
- 17.13.2 REVENUE ANALYSIS 207
- 17.13.3 PRODUCT PORTFOLIO 208
- 17.13.4 RECENT DEVELOPMENT 208
17.14 VIATRIS INC. 209
- 17.14.1 COMPANY SNAPSHOT 209
- 17.14.2 REVENUE ANALYSIS 209
- 17.14.3 PRODUCT PORTFOLIO 210
- 17.14.4 RECENT DEVELOPMENT 210
17.15 VIRTUS 211
- 17.15.1 COMPANY SNAPSHOT 211
- 17.15.2 PRODUCT PORTFOLIO 211
- 17.15.3 RECENT DEVELOPMENT 211

18 QUESTIONNAIRE 212

19 RELATED REPORTS 216

LIST OF TABLES

TABLE 1 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2022-2030 (USD THOUSAND) 66
TABLE 2 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 3 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 4 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 5 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 69
TABLE 6 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 74
TABLE 7 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 8 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 75
TABLE 9 EUROPE IMMUNOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 10 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 11 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 78
TABLE 12 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 78
TABLE 13 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 79
TABLE 14 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 80
TABLE 15 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 81
TABLE 16 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 81
TABLE 17 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 82
TABLE 18 EUROPE OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 19 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 86
TABLE 20 EUROPE GENERICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 21 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 22 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 88
TABLE 23 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2022-2030 (USD THOUSAND) 93
TABLE 24 EUROPE GERIATRIC IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 25 EUROPE ADULTS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 26 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 98
TABLE 27 EUROPE PARENTERAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 28 EUROPE ORAL IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 29 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2022-2030 (USD THOUSAND) 103
TABLE 30 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
TABLE 31 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 32 EUROPE CANCER CENTERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
TABLE 33 EUROPE SPECIALTY CLINICS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
TABLE 34 EUROPE OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 35 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD THOUSAND) 110
TABLE 36 EUROPE DIRECT TENDER IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
TABLE 37 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
TABLE 38 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 39 EUROPE OTHERS IN UTERINE CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD THOUSAND) 113
TABLE 40 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 117
TABLE 41 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 42 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 117
TABLE 43 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 44 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 45 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 118
TABLE 46 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 47 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 119
TABLE 48 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 119
TABLE 49 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 119
TABLE 50 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 51 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 52 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 120
TABLE 53 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 120
TABLE 54 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 121
TABLE 55 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 121
TABLE 56 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 57 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 58 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 59 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 60 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 61 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 62 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 123
TABLE 63 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 64 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 124
TABLE 65 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 66 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 67 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 68 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 69 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 70 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 125
TABLE 71 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 72 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 126
TABLE 73 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 126
TABLE 74 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
TABLE 75 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 76 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 77 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
TABLE 78 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
TABLE 79 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 80 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 81 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 82 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
TABLE 83 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 129
TABLE 84 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 85 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 129
TABLE 86 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 129
TABLE 87 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 88 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 89 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 90 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 91 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 130
TABLE 92 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 131
TABLE 93 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
TABLE 94 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 131
TABLE 95 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
TABLE 96 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
TABLE 97 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
TABLE 98 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 99 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 100 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 101 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 102 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 134
TABLE 103 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 104 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 134
TABLE 105 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 134
TABLE 106 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 107 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 108 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 109 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 135
TABLE 110 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 135
TABLE 111 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 136
TABLE 112 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 136
TABLE 113 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 136
TABLE 114 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
TABLE 115 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 136
TABLE 116 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 117 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 118 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 119 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 120 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 121 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 139
TABLE 122 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
TABLE 123 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 139
TABLE 124 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 139
TABLE 125 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 126 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 127 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 128 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 140
TABLE 129 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 140
TABLE 130 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 141
TABLE 131 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
TABLE 132 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
TABLE 133 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 134 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 135 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 136 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 137 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 138 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 139 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
TABLE 140 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 144
TABLE 141 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 144
TABLE 142 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 144
TABLE 143 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 144
TABLE 144 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 145
TABLE 145 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 146 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 145
TABLE 147 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 148 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 145
TABLE 149 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 146
TABLE 150 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 146
TABLE 151 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 146
TABLE 152 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 153 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 146
TABLE 154 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
TABLE 155 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 156 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 157 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 158 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 148
TABLE 159 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 149
TABLE 160 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 161 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 149
TABLE 162 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 149
TABLE 163 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 150
TABLE 164 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 165 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 150
TABLE 166 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 167 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 150
TABLE 168 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 151
TABLE 169 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 151
TABLE 170 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 151
TABLE 171 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
TABLE 172 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 173 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 152
TABLE 174 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 175 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 176 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 177 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 178 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 154
TABLE 179 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 180 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 154
TABLE 181 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 154
TABLE 182 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 155
TABLE 183 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 184 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 155
TABLE 185 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 155
TABLE 186 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 155
TABLE 187 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 156
TABLE 188 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
TABLE 189 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 156
TABLE 190 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 156
TABLE 191 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 156
TABLE 192 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 193 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 194 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 195 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 196 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 197 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 159
TABLE 198 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 159
TABLE 199 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 159
TABLE 200 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 160
TABLE 201 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 160
TABLE 202 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 203 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 160
TABLE 204 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 160
TABLE 205 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 161
TABLE 206 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 161
TABLE 207 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 161
TABLE 208 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 161
TABLE 209 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 210 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 162
TABLE 211 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 212 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 213 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 214 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
TABLE 215 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 216 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 164
TABLE 217 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 164
TABLE 218 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 164
TABLE 219 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 165
TABLE 220 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 165
TABLE 221 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 222 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 165
TABLE 223 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 224 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 166
TABLE 225 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 166
TABLE 226 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 166
TABLE 227 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 166
TABLE 228 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 229 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 167
TABLE 230 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
TABLE 231 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 232 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 233 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 168
TABLE 234 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 235 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 169
TABLE 236 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
TABLE 237 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 169
TABLE 238 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 170
TABLE 239 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 170
TABLE 240 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 241 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 170
TABLE 242 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND) 170
TABLE 243 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND) 171
TABLE 244 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 171
TABLE 245 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 171
TABLE 246 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND) 171
TABLE 247 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 248 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 172
TABLE 249 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 172
TABLE 250 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND) 173

LIST OF FIGURES

FIGURE 1 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION 28
FIGURE 2 EUROPE UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION 31
FIGURE 3 EUROPE UTERINE CANCER DRUGS MARKET: DROC ANALYSIS 32
FIGURE 4 EUROPE UTERINE CANCER DRUGS MARKET : EUROPE VS REGIONAL MARKET ANALYSIS 33
FIGURE 5 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 EUROPE UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS 35
FIGURE 7 EUROPE UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID 36
FIGURE 8 EUROPE UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID 37
FIGURE 9 EUROPE UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS 38
FIGURE 10 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION 42
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS EXPECTED TO DRIVE THE GROWTH OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 43
FIGURE 12 ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030 43
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE UTERINE CANCER DRUGS MARKET 51
FIGURE 14 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022 64
FIGURE 15 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND) 65
FIGURE 16 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030) 65
FIGURE 17 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE 66
FIGURE 18 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022 72
FIGURE 19 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 73
FIGURE 20 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 73
FIGURE 21 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE 74
FIGURE 22 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022 84
FIGURE 23 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND) 85
FIGURE 24 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030) 85
FIGURE 25 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE 86
FIGURE 26 EUROPE UTERINE CANCER DRUGS MARKET: BY TYPE, 2022 91
FIGURE 27 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND) 92
FIGURE 28 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030) 92
FIGURE 29 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE 93
FIGURE 30 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022 96
FIGURE 31 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 97
FIGURE 32 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 97
FIGURE 33 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 98
FIGURE 34 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2022 101
FIGURE 35 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND) 102
FIGURE 36 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030) 102
FIGURE 37 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE 103
FIGURE 38 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022 108
FIGURE 39 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 109
FIGURE 40 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 109
FIGURE 41 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 110
FIGURE 42 EUROPE UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022) 115
FIGURE 43 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%) 174